Earnings beat expectations. Top line results for second phase 3 clinical trial for pacritinib to be released in next 60 days. Think we could see over $1 again here, might be next EBIO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.